Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.95 USD

45.95
9,987,365

+0.59 (1.30%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $45.64 -0.31 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA

by Zacks Equity Research

Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.

    Zacks Equity Research

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    by Zacks Equity Research

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

      Zacks Equity Research

      Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

      by Zacks Equity Research

      Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.

        Zacks Equity Research

        The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

          Zacks Equity Research

          Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

          by Zacks Equity Research

          Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

            Kinjel Shah headshot

            ASCO Ends: Winners & Losers at the Key Cancer Research Event

            by Kinjel Shah

            The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

              Zacks Equity Research

              Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study

              by Zacks Equity Research

              Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.

                Zacks Equity Research

                Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

                by Zacks Equity Research

                Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.

                  Zacks Equity Research

                  Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

                  by Zacks Equity Research

                  Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

                    Zacks Equity Research

                    Pfizer's Xalkori Gets Breakthrough Status for New Indications

                    by Zacks Equity Research

                    Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications.

                      Zacks Equity Research

                      Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC

                      by Zacks Equity Research

                      Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer.

                        Zacks Equity Research

                        AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study

                        by Zacks Equity Research

                        AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.

                          Zacks Equity Research

                          Why Is Bristol-Myers Squibb (BMY) Up 1.3% Since Its Last Earnings Report?

                          by Zacks Equity Research

                          Bristol-Myers Squibb (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Zacks Equity Research

                            Merck's Keytruda Shows Survival Benefit in Squamous NSCLC

                            by Zacks Equity Research

                            Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.

                              Zacks Equity Research

                              Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

                              by Zacks Equity Research

                              European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

                                Zacks Equity Research

                                Illumina Takes Over Edico Genome, Fortifies NGS Platform

                                by Zacks Equity Research

                                Illumina (ILMN) proceeds with deals to boost NGS platform.

                                  Zacks Equity Research

                                  Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y

                                  by Zacks Equity Research

                                  Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.

                                    Zacks Equity Research

                                    Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

                                    by Zacks Equity Research

                                    Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

                                      Zacks Equity Research

                                      Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

                                      by Zacks Equity Research

                                      Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

                                        Zacks Equity Research

                                        Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall

                                        by Zacks Equity Research

                                        Horizon Pharma (HZNP) misses earnings and sales estimates in Q1. However, the orphan unit and the rheumatology business continue to grow.

                                          Zacks Equity Research

                                          Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

                                          by Zacks Equity Research

                                          Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.

                                            Zacks Equity Research

                                            Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat

                                            by Zacks Equity Research

                                            Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.

                                              Zacks Equity Research

                                              AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

                                              by Zacks Equity Research

                                              AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.

                                                Sweta Killa headshot

                                                Q1 Earnings Drag Pharma ETFs Down

                                                by Sweta Killa

                                                Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.

                                                  Zacks Equity Research

                                                  What's in Store for Celldex (CLDX) This Earnings Season?

                                                  by Zacks Equity Research

                                                  With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.